Following the recent availability of high-throughput data for drug discovery, computational methods, especially machine learning based approaches, have gained remarkable attention.
AVAILABILITY AND REQUIREMENTS
The Jupyter Notebook, named interaction.ipynb containing the code used in this analysis is available in Repurpose framework (github.com/emreg00/ repurpose).
BODY
Following the recent availability of high-throughput data for drug discovery, computational methods, especially machine learning based approaches, have gained remarkable attention. A number of studies use chemical, target and side effect similarity between drugs to build knowledge-based models that predict drug indications and drug-drug interactions [1] [2] [3] . The proposed models are typically benchmarked using cross-validation, in which the known drug-disease or drug-drug associations are split into training and test sets. Though these methods report areas under receiver operating characteristic (ROC) curves around 90% under cross-validation, their applicability in translational medicine and, thus, ability to reduce drug development costs has been controversial [2, 4, 5] .
In light of previous works highlighting the perils of cross-validation using paired data [6, 7] , we recently investigated the effect of using drug-wise disjoint cross-validation in predicting drug-disease pairs, where none of the drugs in the training set appeared in the test set [8] . We showed that the prediction accuracy of the classifier drops dramatically under such cross-validation setting, suggesting that the existing approaches are prone to over-fitting due to the inherent relationships in the data.
Here, we turn our attention to disjoint cross-validation of similarity-based drug-drug interaction (DDI) prediction ( Figure 1 ). Owing to the larger number of known drug-drug interactions, compared to the number of known drug-disease associations used in our previous study, we explore the effect of sample size in the data set. We use the code and data provided within Repurpose framework [8] and train a logistic regression classifier to predict DDIs using drug chemical, target and side effect similarity calculated via a k-nearest-neighbor approach (k = 20, see [8] for details).
In addition to the drug chemical, target and side effect information available at Repurpose, we retrieve drug-drug interactions from DrugBank [9] (v4.5.0), corresponding to 26,484 known drug-drug interactions for 536 drugs in the data set. Next, we test the prediction accuracy of the classifier on truly novel cases, that is, drugs it has never seen before under a ten fold cross-validation scheme. We repeat the cross-validation procedure ten times and calculate the mean and standard deviation of the area under ROC curve (AUC) across these runs. We also implement a pairwise-disjoint cross-validation strategy, by first randomly assigning drugs into groups (cross-validation folds) and then considering only the drug interactions between the drugs within the same group. Similar to our previous observation on drug-disease association prediction, we find that the area under ROC curve (AUC) is lower for DDI prediction using drug similarity when the drug pairs are split such that the interactions of one of the pair appears in the training set but not in the test set ( Figure 2 Cross-validation strategies. Different cross-validation (xval) strategies that can be used in similarity-based drug-drug interaction (DDI) prediction. In the given example data set, DDIs between compounds c 1 , c 2 , c 3 , c 4 , c 5 , c 6 are represented in orange (known interactions) and black (otherwise).
Conventionally, (non-disjoint) k-fold cross-validation randomly splits the data into k groups preserving the overall proportion of the labels in the data. In this example, we ensure that there are two times more negatives than positives, and the drug-drug pairs that are not included -to maintain the 1:2 proportion-in any of the folds are shown in gray. In disjoint cross-validation, the data set is partitioned such that the interactions of one drug are grouped in one cross-validation fold, preventing an overlap across different folds. In pairwise-disjoint cross-validation, the data set is partitioned such that all of the participants of the drug-drug interactions within a cross-validation fold appear in the same fold. Note that there are some drug pairs that can not be included in any of the folds as they would compromise the integrity of the pairwise-disjoint fold.
that a few thousands of positive instances are enough to build a classifier that achieves reasonable AUC and the total number of known (positive) drug-drug interactions used in the analysis has little effect on the prediction accuracy. Interestingly, when the interactions of the drugs are grouped such that none of the drugs in the training set appear in the test set (pairwise-disjoint cross-validation), we obtain similar a similar AUC value to that of disjoint cross-validation (AU C pairwise disjoint = 76.9 vs AU C disjoint = 77.7, using a random sampling of 1,000 positive instances). The small difference in AUC between these two cross-validation approaches is consistent with the previous observations of Park and Marcotte [7] and implies that disjoint cross-validation already gives a representative split of the data toward a more realistic benchmarking.
On the other hand, we observe that the balance between the number of training and test samples affects the AUC substantially and the classifier performs as good as non-disjoint case when the training and test sets contain equal number of instances (i.e. in 2-fold cross-validation). Taken together, these results suggest that the diversity of the data set (e.g., in terms of For the cross-validation analysis, we generate a data set that contains a random sampling of 1,000, 5,000 and 10,000 positive instances, respectively. We sample twice as many negative instances from the drug-drug pairs that are not reported as interacting. Error bars show standard deviation of AUC over ten runs of cross-validation. chemical composition, target and side effect profiles of drugs) is more important than the size of the data set, that is, the number of instances used to calculate similarity-based features and build the model. All in all, our analysis confirms the dependence on the cross-validation strategy used to evaluate prediction accuracy of drug similarity-based classifiers operating on paired data such as pharmacokinetic interactions between drugs. We conclude that to ensure realistic estimates of prediction accuracies, developed machine learning models for DDI prediction should take into account the variety of drugs in the training and test sets. Given the unevenness between data sets used in academic research and in real-world, we argue that using disjoint-cross validation can be beneficial in developing robust machine learning models.
